Navigation Links
12-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions
Date:10/13/2008

'New Class' of Stent with Polyzene(R)-F Surface Treatment Maximizes Endothelialization; Reduces Restenosis, Thrombogenicity, Need for Long-Term Dual Antiplatelet Therapy

WASHINGTON, Oct. 13 /PRNewswire/ -- Clinical investigators at today's "Innovative Devices and Futuristic Therapies" session during the 20th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation, presented 12-month follow-up data from the ATLANTA Trial. The results include zero percent thrombosis in patients discontinuing dual anti-platelet therapy after only 30 days.

The ATLANTA Trial is a first-in-man (FIM), prospective, single center, non-randomized, single-arm study involving 55 patients (76 lesions) treated with the CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F surface modification for symptomatic ischemic heart disease due to de novo, obstructive lesions of native coronary arteries. The trial was sponsored by CeloNova BioSciences, Inc., maker of the CATANIA(TM) stent.

At 12 months, in an unusually complex FIM patient population, the results showed zero (0.0) percent stent thrombosis (Academic Research Consortium, or ARC-defined), death, myocardial infarction, stroke, or coronary artery bypass graft. Target lesion revascularization was 10.9 percent (only 3.6 percent clinically driven, 7.3 percent non-clinically driven), with a binary restenosis rate of 6.8 percent (five of 74 lesions analyzed at twelve months). Of note, all patients stopped dual anti-platelet therapy after 30 days, but continued aspirin (100 mg/d) throughout the 12-month period.

The acute angiographic and procedural success rate in the ATLANTA Trial was 100 percent. Independent core laboratories analyzed quantitative coronary angiography and intravascular ultrasound (IVUS) data for all patients immediately after stent implantation and at 6-month follow-up. Further analysis of 1,904 cross sections (19,028
'/>"/>

SOURCE CeloNova BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system)
2. Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data
3. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
4. Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008
5. SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
6. Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent
7. Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months
8. Texas Cardiac Arrhythmia Institute at St. Davids Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation
9. Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD
10. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial
11. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2008)...tCall/ -- PAREXEL International Corporation (Nasda...rvices provider, today announced that it has opene...nsulting and clinical research capabilities. With ...ocations throughout five important biopharmaceutic...gentina, Brazil, Chile, and Mexico. This expansion...
(Date:11/19/2008)...e statistical significance , , ISELIN, N.J....ration (Nasdaq: PARS ) today announced results f...oEmulsion (NE) drug delivery technology formulated... multi-center, randomized, double-blinded, placebo...y of the Company,s 3% Diclofenac Diethanolamine Na...
(Date:11/19/2008)...m Roche- , , MONTVALE, N.J., Nov. 19 /PRNew...Nasdaq: MEMY ) today announced that it has achie...3487/MEM 3454, its lead alpha-7 nicotinic receptor...schizophrenia (CIAS). The Company has randomized ....0 million payment from its partner Roche. Memory...
(Date:11/18/2008)...ire-USNewswire/ -- Forty-two leading U. S. scienti...l forum to consider cutting-edge innovations that ...onomy from outbreaks of dangerous zoonotic disease...ng those innovations: , , , , A...at detects highly contagious and dangerous zoonoti...
Breaking Medicine Technology:PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 2PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 3PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 4Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 342 Top U.S. Scientists and Specialists Explore Cutting-Edge Innovations to Defend America From Dangerous Zoonotic Diseases 2Nature study demonstrates that bacterial clotting depends on clustering 5691 1Nature study demonstrates that bacterial clotting depends on clustering 5691 2Excess Weight Seems to Boost Breast Cancer Risk 28489 1Excess Weight Seems to Boost Breast Cancer Risk 28489 2Excess Weight Seems to Boost Breast Cancer Risk 28489 3Mayo Clinics new imaging technology accurately identifies a broad spectrum of liver disease 28487 1Mayo Clinics new imaging technology accurately identifies a broad spectrum of liver disease 28487 2Boceprevir Phase II Study Showed High Rate of Sustained Response With 28 and 48 Week Regimens in Genotype 1 Treatment Naive Hepatitis C Patients 3377 1Boceprevir Phase II Study Showed High Rate of Sustained Response With 28 and 48 Week Regimens in Genotype 1 Treatment Naive Hepatitis C Patients 3377 2Boceprevir Phase II Study Showed High Rate of Sustained Response With 28 and 48 Week Regimens in Genotype 1 Treatment Naive Hepatitis C Patients 3377 3Boceprevir Phase II Study Showed High Rate of Sustained Response With 28 and 48 Week Regimens in Genotype 1 Treatment Naive Hepatitis C Patients 3377 4Boceprevir Phase II Study Showed High Rate of Sustained Response With 28 and 48 Week Regimens in Genotype 1 Treatment Naive Hepatitis C Patients 3377 5Boceprevir Phase II Study Showed High Rate of Sustained Response With 28 and 48 Week Regimens in Genotype 1 Treatment Naive Hepatitis C Patients 3377 6Boceprevir Phase II Study Showed High Rate of Sustained Response With 28 and 48 Week Regimens in Genotype 1 Treatment Naive Hepatitis C Patients 3377 7Boceprevir Phase II Study Showed High Rate of Sustained Response With 28 and 48 Week Regimens in Genotype 1 Treatment Naive Hepatitis C Patients 3377 8Boceprevir Phase II Study Showed High Rate of Sustained Response With 28 and 48 Week Regimens in Genotype 1 Treatment Naive Hepatitis C Patients 3377 9Boceprevir Phase II Study Showed High Rate of Sustained Response With 28 and 48 Week Regimens in Genotype 1 Treatment Naive Hepatitis C Patients 3377 10
...h VELCADE, lenalidomide,and dexamethasone , ,KOS, ...um,Pharmaceuticals, Inc. (Nasdaq: MLNM) today repo...ical trials of VELCADE based,therapies that showed... / complete response(1) (CR) rates in newly diagno...e presented at the,prestigious 11th International ...
..., 2007 - The drug most,commonly used to arrest pre... another common treatment to cause mild to serious...udy from researchers at,Lucile Packard Children,s ...e. Their findings suggest that, since the effectiv... should consider side,effects more strongly when c...
Other Medicine Technology:Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 2Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 3Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 4Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 5Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 6Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 7Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 8Common Preterm Labor Drug Has More Side Effects Than Alternative,Finds Study from Packard Children's Hospital and Stanford 2Common Preterm Labor Drug Has More Side Effects Than Alternative,Finds Study from Packard Children's Hospital and Stanford 3Common Preterm Labor Drug Has More Side Effects Than Alternative,Finds Study from Packard Children's Hospital and Stanford 4
(Date:11/21/2008)...VALE, N.J., Nov. 21 Barr...ced that its shareholders overwhelmingly approved ...quisition of Barr by Teva Pharmaceuticals Industri...te demonstrated the overwhelming support of the tr... Downey, Barr,s Chairman and CEO. "We are pleased ...
(Date:11/21/2008)... 430 B.C., a new and deadly diseaseits cause remai...ty-state was teeming with citizens, soldiers and r...Sparta. As streets filled with corpses, social ord...ess returned twice and Athens lost a third of its ...ens marked the beginning of the end of the Golden ...
(Date:11/21/2008)...ROCHELLE, N.Y., Nov. 21 A prestigi...care providers will gather in Williamsburg, VA on ...rn practical, clinical information on cutting-edge...s, and innovative research advances that impact pa...on, and registration information is available at ...
(Date:11/21/2008)...NEW YORK Tobacco use is more prevalent and smok...tion Deficit Hyperactivity Disorder (A.D.H.D.) In...eractivity symptoms, those who exhibited elevated ...ttention, showed lower quit rates after 8 weeks th...without the A.D.H.D. symptoms. The study, now ava...
Breaking Medicine News(10 mins):Health News:Barr Shareholders Approve Pending Teva Acquisition 2Health News:Barr Shareholders Approve Pending Teva Acquisition 3Health News:Barr Shareholders Approve Pending Teva Acquisition 4Health News:Study of ancient and modern plagues finds common features 2Health News:Study of ancient and modern plagues finds common features 3Health News:Study of ancient and modern plagues finds common features 4Health News:17th Annual Congress on Women's Health Convenes March 27-29, 2009 in Williamsburg, VA 2Health News:Ability to quit smoking may depend on ADHD symptoms, Columbia researchers find 2
... 23rd man had succumbed to the deadly H5N1 bird fl...an has tested// positive to the same virus. The H5...e over Europe and Africa and has flared up once ag...lth Organization, some 105 people have fallen a vi...
...eople on vegetarian diets have highly effective we...er// than meat-eaters, and they experience lower r...re, and other life-threatening conditions linked t...lied from 87 previous studies and it shows the wei...
...ite making in-depth analysis in the field of atten...ychiatric problem that affects the children. As ...cation, which is beyond the scientists' control, b...gsters diagnosed with ADHD suffer co-existing cond...
... in cancer patients, as a new method of delivering...thout causing any side effects such as hair loss a... at the University of Bath, England, involves usin...emotherapy drug, which are then implanted into the...
Other Medicine News:Health News:Despite More Studies Researchers Are Still Confound With ADHD 2Health News:New Method Developed To Cut Down Chemotherapy Deaths 2
...m DePuy offers a comprehensive combination of comf...commendations regarding occupational exposure to b...d for comfort. , ,The Nighthawk, a new additio...personal protection system for the healthcare prof...
Ideal for sensory nerve testing, Cadwells finger clip electrodes are constructed of solid, surgical-grade stainless steel and come with color-coded handles and ultra-flexible, red-and-black twisted p
Cadwells stainless steel ring electrodes feature a molded grip for convenient handling and an adjustable slider that moves smoothly and locks firmly in one motion. Cadwell rings also feature ultrafle
Silver/silver chloride ground has a large surface area for superb patient grounding. For use with minicrocodile clip lead wires. Dimensions: 4.5 cm (1.75 in) long, 3.1 cm (1.25 in) wide. Each 100-cou
Medicine Products: